These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33087332)

  • 1. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.
    Simonetta F; Alam IS; Lohmeyer JK; Sahaf B; Good Z; Chen W; Xiao Z; Hirai T; Scheller L; Engels P; Vermesh O; Robinson E; Haywood T; Sathirachinda A; Baker J; Malipatlolla MB; Schultz LM; Spiegel JY; Lee JT; Miklos DB; Mackall CL; Gambhir SS; Negrin RS
    Clin Cancer Res; 2021 Feb; 27(4):1058-1068. PubMed ID: 33087332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy.
    Xiao Z; Mayer AT; Nobashi TW; Gambhir SS
    Cancer Res; 2020 Jul; 80(14):3023-3032. PubMed ID: 32156777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-PET Monitoring of CD8
    Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
    Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model.
    Kim SY; Soh H; Jung JH; Cho EH; Kim H; Ju JM; Sheen JH; Lee SJ; Oh SJ; Lee SJ; Chung J; Ryu JS
    Radiology; 2024 Feb; 310(2):e231406. PubMed ID: 38411517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.
    Xiao Z; Alam IS; Simonetta F; Chen W; Scheller L; Murty S; Lohmeyer JK; Ramos TL; James ML; Negrin RS; Gambhir SS
    Blood Adv; 2022 Aug; 6(16):4782-4792. PubMed ID: 35790103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
    Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
    Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of
    Wang XY; Wang Y; Wu Q; Liu JJ; Liu Y; Pan DH; Qi W; Wang LZ; Yan JJ; Xu YP; Wang GJ; Miao LY; Yu L; Yang M
    Acta Pharmacol Sin; 2021 May; 42(5):824-831. PubMed ID: 32901086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
    Volpe A; Lang C; Lim L; Man F; Kurtys E; Ashmore-Harris C; Johnson P; Skourti E; de Rosales RTM; Fruhwirth GO
    Mol Ther; 2020 Oct; 28(10):2271-2285. PubMed ID: 32645298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
    Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
    JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models.
    Zheng L; Ren L; Kouhi A; Khawli LA; Hu P; Kaslow HR; Epstein AL
    Clin Cancer Res; 2020 Jul; 26(14):3694-3706. PubMed ID: 32273277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.
    Shao F; Long Y; Ji H; Jiang D; Lei P; Lan X
    Theranostics; 2021; 11(14):6800-6817. PubMed ID: 34093854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
    Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatio-temporal biodistribution of
    Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE
    Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.